Movement Alert｜CSPC Pharmaceutical Group Rises 3.14% in Regular Trading, Chairman Nearly HK$100 Million Share Purchase Coupled with Subsidiary Re-filing for HKEX Listing

Market Focus06-24

On June 24, CSPC Pharmaceutical Group rose 3.14% in regular trading, trading at HK$6.91/share, with turnover of HK$377 million. Multiple positive catalysts converged to boost market confidence.

On the news front, the company disclosed on June 22 that Executive Director and Chairman Cai Dongchen purchased 14.65 million shares at an average price of HK$6.8253, totaling approximately HK$99.99 million, raising his stake to 26.39%. Additionally, indirect subsidiary CSPC Innovation submitted a fresh H-share listing application to HKEX on June 18 after its previous application lapsed. The trustee under the share award plan also purchased 5.8 million shares on June 22.

Further supporting sentiment, Guojin Securities recently initiated coverage with a Buy rating, assigning a target market capitalization of approximately HK$137.9 billion, implying significant upside from current levels. The company also secured FDA approval for clinical trials of its Octreotide Long-acting Injection and received NMPA acceptance for a second indication of Edaglutide Alpha Injection.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197555622?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 11:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197555622","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Group Rises 3.14% in Regular Trading, Chairman Nearly HK$100 Million Share Purchase Coupled with Subsidiary Re-filing for HKEX Listing","media":"Market Focus","content":"<p><p>On June 24, CSPC Pharmaceutical Group rose 3.14% in regular trading, trading at HK$6.91/share, with turnover of HK$377 million. Multiple positive catalysts converged to boost market confidence.</p><p>On the news front, the company disclosed on June 22 that Executive Director and Chairman Cai Dongchen purchased 14.65 million shares at an average price of HK$6.8253, totaling approximately HK$99.99 million, raising his stake to 26.39%. Additionally, indirect subsidiary CSPC Innovation submitted a fresh H-share listing application to HKEX on June 18 after its previous application lapsed. The trustee under the share award plan also purchased 5.8 million shares on June 22.</p><p>Further supporting sentiment, Guojin Securities recently initiated coverage with a Buy rating, assigning a target market capitalization of approximately HK$137.9 billion, implying significant upside from current levels. The company also secured FDA approval for clinical trials of its Octreotide Long-acting Injection and received NMPA acceptance for a second indication of Edaglutide Alpha Injection.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Group Rises 3.14% in Regular Trading, Chairman Nearly HK$100 Million Share Purchase Coupled with Subsidiary Re-filing for HKEX Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Group Rises 3.14% in Regular Trading, Chairman Nearly HK$100 Million Share Purchase Coupled with Subsidiary Re-filing for HKEX Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 11:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, CSPC Pharmaceutical Group rose 3.14% in regular trading, trading at HK$6.91/share, with turnover of HK$377 million. Multiple positive catalysts converged to boost market confidence.</p><p>On the news front, the company disclosed on June 22 that Executive Director and Chairman Cai Dongchen purchased 14.65 million shares at an average price of HK$6.8253, totaling approximately HK$99.99 million, raising his stake to 26.39%. Additionally, indirect subsidiary CSPC Innovation submitted a fresh H-share listing application to HKEX on June 18 after its previous application lapsed. The trustee under the share award plan also purchased 5.8 million shares on June 22.</p><p>Further supporting sentiment, Guojin Securities recently initiated coverage with a Buy rating, assigning a target market capitalization of approximately HK$137.9 billion, implying significant upside from current levels. The company also secured FDA approval for clinical trials of its Octreotide Long-acting Injection and received NMPA acceptance for a second indication of Edaglutide Alpha Injection.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1197555622","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197555622","pubTimestamp":1782270764,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, CSPC Pharmaceutical Group rose 3.14% in regular trading, trading at HK$6.91/share, with turnover of HK$377 million. Multiple positive catalysts converged to boost market confidence.On the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"动向快讯|石药集团常规交易涨3.14%董事长近亿港元购股叠加子公司重新申请港交所上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On June 24, CSPC Pharmaceutical Group rose 3.14% in regular trading, trading at HK$6.91/share, with turnover of HK$377 million. Multiple positive catalysts converged to boost market confidence.On the news front, the company disclosed on June 22 that Executive Director and Chairman Cai Dongchen purchased 14.65 million shares at an average price of HK$6.8253, totaling approximately HK$99.99 million, raising his stake to 26.39%. Additionally, indirect subsidiary CSPC Innovation submitted a fresh H-share listing application to HKEX on June 18 after its previous application lapsed. The trustee under the share award plan also purchased 5.8 million shares on June 22.Further supporting sentiment, Guojin Securities recently initiated coverage with a Buy rating, assigning a target market capitalization of approximately HK$137.9 billion, implying significant upside from current levels. The company also secured FDA approval for clinical trials of its Octreotide Long-acting Injection and received NMPA acceptance for a second indication of Edaglutide Alpha Injection.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197555622","isCrawlerRequest":true}